Diazepam intranasal - Neurelis

Drug Profile

Diazepam intranasal - Neurelis

Alternative Names: NRL-01; NRL-1

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Neurelis
  • Class Antiepileptic drugs; Anxiolytics; Benzodiazepines; Benzodiazepinones; Hypnosedatives; Muscle relaxants; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epilepsy
  • New Molecular Entity No

Highest Development Phases

  • Phase III Epilepsy

Most Recent Events

  • 05 Jan 2017 Neurelis plans to file an NDA application with the US FDA in for Epilepsy
  • 04 Jan 2017 Diazepam intranasal - Neurelis receives Fast Track designation for Epilepsy [Intranasal,Spray] (Treatment-experienced) in USA
  • 01 Jul 2016 Neurelis initiates enrolment in a phase I trial for Epilepsy in USA (NCT02724423)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top